Fenbendazole Encapsulated by Cucurbiturils: New Nanocarrier Design for Cancer Drug Delivery (2026)

Fenbendazole, a benzimidazole anthelmintic originally developed for veterinary parasitic infections, has gained attention in recent years for its preclinical anticancer activity across multiple tumor types. However, a major obstacle to its clinical translation is its poor aqueous solubility, which severely limits absorption and bioavailability in human patients. Researchers are increasingly exploring nanocarrier-based drug delivery systems to overcome this pharmacological barrier, and a new computational study offers fresh insights into one promising approach. Patients and researchers interested in dosing strategies for repurposed agents can reference the dosing calculator as a structured resource.

Published in the Journal of Molecular Graphics and Modelling in 2026, the study used density functional theory (DFT)—a quantum mechanical modeling method—to simulate how fenbendazole interacts with cucurbituril macrocycles, a class of barrel-shaped host molecules that can encapsulate guest drug compounds. The researchers compared two cucurbituril variants: CB[7] and CB[8], differing in cavity size. By analyzing structural, electronic, thermodynamic, and spectroscopic parameters, the team mapped the energetics and stability of fenbendazole encapsulation within each host.

For readers seeking broader context on how fenbendazole fits into the landscape of repurposed benzimidazoles, the fenbendazole vs. mebendazole comparison provides a detailed breakdown of structural similarities, mechanistic differences, and clinical positioning. Those researching brain tumor applications may also find the fenbendazole and glioblastoma overview relevant for understanding the blood-brain barrier considerations that make solubility enhancement especially critical.

Table of Contents

• Why Solubility Matters for Fenbendazole
• Computational Methods and Findings
• Cucurbituril as a Drug Delivery Platform
• Implications for Cancer Therapy
• Frequently Asked Questions

Why Solubility Matters for Fenbendazole

Fenbendazole's poor aqueous solubility is a well-documented pharmacokinetic limitation. In oral dosing, low solubility reduces the fraction of drug absorbed from the gastrointestinal tract, leading to variable plasma concentrations and unpredictable systemic exposure. For cancer applications—where consistent dosing is critical to achieve therapeutic concentrations in tumor tissue—this variability is a serious concern.

Furthermore, high doses of poorly soluble drugs can require large capsule volumes or frequent dosing, which reduces patient compliance. The veterinary-grade formulations (e.g., Panacur C) that some patients have self-administered are not designed for human pharmacokinetics and contain excipients that may pose additional safety risks. For a detailed discussion of veterinary vs. pharmaceutical-grade formulations, see the benzimidazole comparison guide.

Computational Methods and Findings

The study employed density functional theory (DFT) calculations to model the three-dimensional structure of fenbendazole within the cucurbituril cavities. DFT is a widely used computational chemistry method that predicts molecular geometries, electronic properties, and reaction energetics by solving the Schrödinger equation for electron density rather than for the full wavefunction.

Key findings from the computational analysis included:

Host-guest geometry: Fenbendazole was found to fit within both CB[7] and CB[8] cavities, with the larger CB[8] providing more spatial freedom and potentially accommodating multiple fenbendazole molecules or co-guests. The smaller CB[7] formed a tighter, more constrained inclusion complex.

Thermodynamic stability: Binding energy calculations indicated favorable encapsulation energetics for both hosts, suggesting that fenbendazole would spontaneously associate with cucurbituril under physiological conditions. The exact binding free energies were not reported in the available abstract.

Electronic properties: DFT-derived frontier molecular orbitals (HOMO and LUMO) and electrostatic potential maps revealed how encapsulation alters the electronic distribution of fenbendazole. These changes can influence the drug's reactivity and its interaction with biological targets such as tubulin.

Spectroscopic predictions: Theoretical infrared (IR) and ultraviolet-visible (UV-Vis) spectra were generated to provide experimental signatures that could guide future laboratory validation of the encapsulation complex.

Cucurbituril as a Drug Delivery Platform

Cucurbiturils are a family of macrocyclic host molecules made from glycoluril units linked by methylene bridges. They have a hydrophobic interior cavity and polar carbonyl portals at both rims, making them ideal for encapsulating hydrophobic drug molecules while maintaining water solubility through the charged portals.

Unlike more commonly discussed nanocarriers such as liposomes, polymeric micelles, or lipid nanoparticles, cucurbiturils are molecular-scale containers rather than colloidal particles. This means they can potentially cross biological membranes through different transport mechanisms and may avoid the reticuloendothelial system (RES) uptake that often clears larger nanoparticles from circulation.

The study also explored the potential for cucurbituril to serve as a building block for more complex supramolecular assemblies. For example, CB[8] can host two guests simultaneously, opening the door to co-delivery systems where fenbendazole is paired with a targeting ligand or a synergistic agent.

Implications for Cancer Therapy

While the study is purely computational, it addresses a real and pressing need in the fenbendazole repurposing field. Improved solubility and stability through supramolecular encapsulation could translate to:

More predictable pharmacokinetics: Encapsulated fenbendazole may exhibit more consistent absorption profiles, enabling better dose optimization and reducing the inter-patient variability seen with raw powder formulations.

Reduced dosing requirements: Enhanced bioavailability could mean that lower doses achieve the same systemic exposure, potentially improving the safety margin and reducing the risk of gastrointestinal or hepatic adverse effects.

Tumor-targeting potential: Functionalized cucurbiturils or their assemblies could be decorated with ligands that recognize tumor-specific markers, enabling active targeting rather than passive distribution.

It is critical to emphasize that no experimental validation—let alone animal or human studies—has been reported for the CB[7]/CB[8]-fenbendazole system. Computational modeling provides hypotheses and guides experimental design, but cannot demonstrate therapeutic efficacy or safety. All translational steps remain ahead.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested fenbendazole products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Computational insights into fenbendazole encapsulation by Cucurbit[n]urils (n = 7, 8). J Mol Graph Model. 2026. PMID: 42013618.

Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. The research described is computational (in-silico modeling) and has not been validated in laboratory, animal, or human studies. Always consult a qualified healthcare provider before making any decisions about cancer treatment, drug use, or dietary changes. Sanare Lab does not provide personalized medical advice and does not endorse self-treatment with investigational agents.